Market Overview:
The global ectonucleotide pyrophosphatase market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of fibrosis, increasing demand for novel therapies for liver fibrosis, and growing awareness about ovarian cancer. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The ectonucleotide pyrophosphatase market can be segmented on the basis of type into GLPG-1690, ONO-8430506, PAT-048, PAT-505 and others. The GLPG-1690 segment is expected to account for a major share of the global ectonucleotide pyrophosphatase market during the forecast period owing to its high efficacy in treating various indications such as fibrosis and liver fibrosis.
Product Definition:
A nucleotide pyrophosphatase that specifically hydrolyzes the 2'-O-phosphate of RNA, EC 3.1.
GLPG-1690:
GLPG-1690 is a selective inhibitor of the ectonucleotide pyrophosphatase (ENPPase) enzyme. ENPPases are involved in the dephosphorylation of phosphomonoesters and phosphotriesters, which results in their breakdown to form nucleosides and free phosphate.
ONO-8430506:
ONO-8430506 is a novel oral phosphatase inhibitor developed by Novartis AG. It is an analog of ONO-5430306 and has been reported to be more efficacious in vitro and in vivo than any other currently approved phosphatase inhibitors.
Application Insights:
The global ectonucleotide pyrophosphatase market is segmented based on application into fibrosis, liver fibrosis, ovarian cancer, musculoskeletal pain and others. Fibrosis was estimated to be the largest revenue-generating segment in 2017 owing to the increasing incidence of chronic kidney disease and other associated disorders that result in increased blood levels of phosphorus. This has led to an increase in demand for phosphate binders across the globe.
Ovarian cancer is estimated to be one of the fastest-growing segments over the forecast period due largely to rising awareness about early detection coupled with improved treatment options available for this condition. In addition, high incidences of gynecological cancers are observed mostly among women above 45 years globally which is expected further drive demand for ectonucleotide pyrophosphatase during this period as well as future ones.
Regional Analysis:
North America dominated the global ectonucleotide pyrophosphatase market in 2017. This can be attributed to the local presence of key players, high disposable income, and increasing awareness about early diagnosis. Moreover, a rise in R&D activities by various companies is expected to fuel regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to unmet clinical needs coupled with rapidly improving healthcare infrastructure and economic development in emerging countries such as China and India. Furthermore, growing investments by major pharmaceutical companies for acquiring new patents will drive regional demand further. For instance, GlaxoSmithKline has filed patent applications for GLPG-1690 related compounds in India (patent application number: 2015025692).
Growth Factors:
- Increasing demand for nucleic acids in life science research
- Growing application of ectonucleotide pyrophosphatase in diagnostics and therapeutics
- Rising investments by biotechnology and pharmaceutical companies for R&D of new drugs
- Technological advancements in the field of nucleic acid analysis
- Growing awareness about the benefits of ectonucleotide pyrophosphatase
Scope Of The Report
Report Attributes
Report Details
Report Title
Ectonucleotide Pyrophosphatase Market Research Report
By Type
GLPG-1690, ONO-8430506, PAT-048, PAT-505, Others
By Application
Fibrosis, Liver Fibrosis, Ovarian Cancer, Musculoskeletal Pain, Others
By Companies
Eli Lilly and Co, Galapagos NV, Ono Pharmaceutical Co Ltd, Ribomic Inc, TaiwanJ Pharmaceuticals Co Ltd, Eli Lilly and Co
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Ectonucleotide Pyrophosphatase Market Report Segments:
The global Ectonucleotide Pyrophosphatase market is segmented on the basis of:
Types
GLPG-1690, ONO-8430506, PAT-048, PAT-505, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Fibrosis, Liver Fibrosis, Ovarian Cancer, Musculoskeletal Pain, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Co
- Galapagos NV
- Ono Pharmaceutical Co Ltd
- Ribomic Inc
- TaiwanJ Pharmaceuticals Co Ltd
- Eli Lilly and Co
Highlights of The Ectonucleotide Pyrophosphatase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- GLPG-1690
- ONO-8430506
- PAT-048
- PAT-505
- Others
- By Application:
- Fibrosis
- Liver Fibrosis
- Ovarian Cancer
- Musculoskeletal Pain
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ectonucleotide Pyrophosphatase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ectonucleotide pyrophosphatase is an enzyme that catalyzes the conversion of ectonucleotides to their corresponding polyphosphates. This reaction is important for the synthesis of DNA and RNA, as well as other cellular proteins.
Some of the major companies in the ectonucleotide pyrophosphatase market are Eli Lilly and Co, Galapagos NV, Ono Pharmaceutical Co Ltd, Ribomic Inc, TaiwanJ Pharmaceuticals Co Ltd, Eli Lilly and Co.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ectonucleotide Pyrophosphatase Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ectonucleotide Pyrophosphatase Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ectonucleotide Pyrophosphatase Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ectonucleotide Pyrophosphatase Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ectonucleotide Pyrophosphatase Market Size & Forecast, 2020-2028
4.5.1 Ectonucleotide Pyrophosphatase Market Size and Y-o-Y Growth
4.5.2 Ectonucleotide Pyrophosphatase Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 GLPG-1690
5.2.2 ONO-8430506
5.2.3 PAT-048
5.2.4 PAT-505
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Fibrosis
6.2.2 Liver Fibrosis
6.2.3 Ovarian Cancer
6.2.4 Musculoskeletal Pain
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ectonucleotide Pyrophosphatase Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ectonucleotide Pyrophosphatase Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 GLPG-1690
9.6.2 ONO-8430506
9.6.3 PAT-048
9.6.4 PAT-505
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Fibrosis
9.10.2 Liver Fibrosis
9.10.3 Ovarian Cancer
9.10.4 Musculoskeletal Pain
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 GLPG-1690
10.6.2 ONO-8430506
10.6.3 PAT-048
10.6.4 PAT-505
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Fibrosis
10.10.2 Liver Fibrosis
10.10.3 Ovarian Cancer
10.10.4 Musculoskeletal Pain
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 GLPG-1690
11.6.2 ONO-8430506
11.6.3 PAT-048
11.6.4 PAT-505
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Fibrosis
11.10.2 Liver Fibrosis
11.10.3 Ovarian Cancer
11.10.4 Musculoskeletal Pain
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 GLPG-1690
12.6.2 ONO-8430506
12.6.3 PAT-048
12.6.4 PAT-505
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Fibrosis
12.10.2 Liver Fibrosis
12.10.3 Ovarian Cancer
12.10.4 Musculoskeletal Pain
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 GLPG-1690
13.6.2 ONO-8430506
13.6.3 PAT-048
13.6.4 PAT-505
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Fibrosis
13.10.2 Liver Fibrosis
13.10.3 Ovarian Cancer
13.10.4 Musculoskeletal Pain
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ectonucleotide Pyrophosphatase Market: Competitive Dashboard
14.2 Global Ectonucleotide Pyrophosphatase Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly and Co
14.3.2 Galapagos NV
14.3.3 Ono Pharmaceutical Co Ltd
14.3.4 Ribomic Inc
14.3.5 TaiwanJ Pharmaceuticals Co Ltd
14.3.6 Eli Lilly and Co
